Partner Search Form
Horizon Europe
Health

Date: 6 October 2026 | Deadline: see topics

CONTACT

Organisation	VascuBio Innovation Inc.	**Department**	R&D / Tissue Engineering
Contact person	Pooya Saberi, CEO & Co-founder	**Email**	psaberi@vascubio.com
City	Toronto, Ontario	**Website**	https://vascubio.com
Country	Canada		

Organisation type

Research organisation type	☐ Research Organisation ☐ University ☒ Company ☐ Other	SME* (company self-description) Number of employees: to confirm	☒ YES ☐ NO

Your enterprise is an SME if:
- it is engaged in **economic activity**
- it has **less than 250 employees**
- it has either an **annual turnover not exceeding €50M**, **or an balance sheet total not exceeding €43M**
- it is **autonomous**

For the definition of SMEs, look at: http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

VascuBio is a Canadian biotechnology company developing vascularised human tissue models, with an initial blood–brain barrier focus. We combine engineered vascular networks, proprietary biomaterials, microfluidics and controlled perfusion to support tissue engineering, disease modelling and drug evaluation. We also develop bioreactor and diagnostic technologies.

Former participation in a funded FP European project?

☐ YES ☒ NO

No funded participation confirmed. Proposal experience: IMMUNEXUS (Horizon Europe; unsuccessful). Contribution: platform engineering and standardisation.

Expertise / Commitment offered

Description of your expertise:

Microfluidic platform and bioreactor engineering; vascularised tissue and BBB models; biomaterials and high-resolution biomedical 3D printing; controlled perfusion. Potential contribution: vascularisation, perfusion and model-development work packages, adapted to consortium requirements.

Keywords specifying your expertise:

Bioprinting; vascularisation; organ-on-chip; blood–brain barrier; microfluidics; perfusion; biomaterials; drug screening; tissue engineering.

Commitment offered:

☒ Research ☒ Demonstration ☐ Training
☒ Technology ☐ Dissemination ☐ Other:

Partner Search Form
Horizon Europe
Health

Interested in participation in project types:	☒ Research & Innovation Action	☒ Innovation Action	☐ EIC Pathfinder

Work Programme research areas: indicate your interest

Horizon Europe Cluster 1 – Health: regenerative medicine and living-cell bioprinting; personalised drug safety; neurodegenerative disease research; point-of-care diagnostics.

Call topics (2027):
• HORIZON-HLTH-2027-03-TOOL-02 – living-cell bioprinting (primary interest; deadline 16 September 2027).
• HORIZON-HLTH-2027-01-CARE-02 – adverse drug reactions in multiple-medication use (deadline 17 February 2027).
• HORIZON-HLTH-2027-02-DISEASE-14-two-stage – neurodegenerative clinical trials.
• HORIZON-HLTH-2027-02-IND-02-two-stage – portable / versatile point-of-care diagnostics.
Two-stage deadlines: 17 February and 16 September 2027. Other topics are exploratory, subject to a suitable consortium and work package.

Do you have other partners for this topic (which partners/country)?	No partners committed to these calls yet. Prior Horizon proposal collaboration with CIC Salamanca / CSIC (Spain). European partner discussions planned around MicroTAS 2026; topic-specific participation to be agreed.

Profile of partner sought

Role	☒ technology development	☒ research	☐ training
	☐ dissemination	☒ demonstration	other: consortium coordination
Country /region	EU Member States and Horizon Europe Associated Countries; especially partners with complementary clinical and translational expertise.		
Expertise required	Experienced coordinators; living-cell bioprinting, regenerative medicine and tissue-engineering teams; clinical partners; GMP manufacturing and regulatory specialists. For other calls: pharmacology / polypharmacy, neurodegenerative clinical-trial teams, or diagnostic developers with clinical-validation expertise. Seeking complementary partnerships where our vascularisation, perfusion, biomaterials and modelling capabilities add value.		

I agree with the publication of my contact data: ☐ YES ☐ NO
For Pooya to select before circulation.